IDEAYA Biosciences, Inc.
IDYA
$18.58
-$0.38-2.00%
Weiss Ratings | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Very Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.40 | |||
Price History | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -2.57% | |||
30-Day Total Return | -23.70% | |||
60-Day Total Return | -28.68% | |||
90-Day Total Return | -35.04% | |||
Year to Date Total Return | -26.15% | |||
1-Year Total Return | -58.06% | |||
2-Year Total Return | 19.95% | |||
3-Year Total Return | 56.27% | |||
5-Year Total Return | 457.96% | |||
52-Week High % Change | -59.96% | |||
52-Week Low % Change | 9.62% | |||
Price | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $46.40 | |||
52-Week Low Price | $16.95 | |||
52-Week Low Price (Date) | Mar 11, 2025 | |||
52-Week High Price (Date) | Mar 21, 2024 | |||
Valuation | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 1.63B | |||
Enterprise Value | 563.46M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -3.30 | |||
Earnings Per Share Growth | 67.97% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 231.96 | |||
Price/Book (Q) | 1.52 | |||
Enterprise Value/Revenue (TTM) | 80.49 | |||
Price | $18.58 | |||
Enterprise Value/EBITDA (TTM) | -1.74 | |||
Enterprise Value/EBIT | -1.72 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 87.34M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 650 443 6209 | |||
Address | 5000 Shoreline Court South San Francisco, CA 94080 | |||
Website | www.ideayabio.com | |||
Country | United States | |||
Year Founded | 2015 | |||
Profitability | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -4,671.07% | |||
Profit Margin | -3,921.10% | |||
Management Effectiveness | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -23.05% | |||
Return on Equity | -- | |||
Income Statement | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 7.00M | |||
Total Revenue (TTM) | 7.00M | |||
Revenue Per Share | $0.08 | |||
Gross Profit (TTM) | -287.67M | |||
EBITDA (TTM) | -324.59M | |||
EBIT (TTM) | -326.98M | |||
Net Income (TTM) | -274.48M | |||
Net Income Avl. to Common (TTM) | -274.48M | |||
Total Revenue Growth (Q YOY) | 78.48% | |||
Earnings Growth (Q YOY) | -283.78% | |||
EPS Diluted (TTM) | -3.30 | |||
EPS Diluted Growth (Q YOY) | -186.70% | |||
Balance Sheet | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 676.32M | |||
Cash Per Share (Q) | $7.74 | |||
Total Current Assets (Q) | 689.71M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 1.06B | |||
Current Ratio (Q) | 14.971 | |||
Book Value Per Share (Q) | $12.24 | |||
Total Assets (Q) | 1.12B | |||
Total Current Liabilities (Q) | 46.07M | |||
Total Debt (Q) | 19.17M | |||
Total Liabilities (Q) | 64.94M | |||
Total Common Equity (Q) | 1.06B | |||
Cash Flow | IDYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -502.56M | |||
Cash from Financing (TTM) | 677.55M | |||
Net Change in Cash (TTM) | -72.59M | |||
Levered Free Cash Flow (TTM) | -160.97M | |||
Cash from Operations (TTM) | -247.58M | |||